Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Articles by Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
Assessing HER2 Expression in Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
Colorectal Cancer: Evolving Role of ctDNA Testing in Practice
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
Biomarker Testing in Metastatic Colorectal Cancer
ByJohn Marshall, MD, Georgetown University Lombardi Comprehensive Cancer Center,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Tanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Aparna R. Parikh, MD,Stacey A. Cohen, MD Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
Colorectal Cancer: An Overview on Molecular Profiling
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.
Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.
Exciting Treatment Opportunities in mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Closing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.
Decisions for Sequencing Therapy for HER2-Expressing mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Considerations regarding best sequencing strategies with novel therapies to treat HER2-mutated metastatic colorectal cancer.
Novel Therapies for HER2-Expressing mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Implications for treating patients with HER2-expressing metastatic colorectal cancer with novel agents such as trastuzumab deruxtecan and tucatinib.
Novel Combinations Being Investigated for mCRC Treatment
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Current trials exploring novel combinations that show potential in making microsatellite stable tumors hot and amenable to response to immunotherapy in metastatic colon cancer.
Dual I-O Therapy for mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Drs Cathy Eng and Joleen M. Hubbard discuss the rationale for studying dual immunotherapy approaches for metastatic colorectal cancer treatment.
Best Practices Surrounding IO Treatment for mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Kanwal Raghav, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses when it is most appropriate to initiate immunotherapy for metastatic colorectal cancer, highlighting the roles of tumor mutation burden and microsatellite instability as biomarkers for treatment.
Frontline I-O Treatment for mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Cathy Eng, MD, FACP, FASCO, describes data revealed by the KEYNOTE-177 trial and discusses best practices for using immunotherapy as first-line treatment of metastatic colorectal cancer.
Biomarker Testing and Precision Medicine in mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute A panel of gastrointestinal oncologists discuss current options for molecular testing based on the understanding that predictive biomarkers play a role in the management of metastatic colon cancer.
Fruquintinib for Refractory mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Expectations regarding the use of fruquintinib, an oral VEGF tyrosine kinase inhibitor, as third-line therapy for metastatic colorectal cancer.
Best Strategies for Sequencing Regorafenib in mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Considerations for how to sequence therapy with regorafenib for relapsed or refractory metastatic colorectal cancer based on the REVERCE II study.
TAS-102 for Refractory mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Variables that impact patient selection for TAS-102 treatment as later-line therapy for metastatic colorectal cancer and considerations for using TAS-102 in combination with bevacizumab.
Regorafenib as Later-Line Treatment for mCRC
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute The rationale for treating metastatic colon cancer with regorafenib in a later-line setting and the importance of applying the dose-escalation strategy demonstrated by the ReDOS trial into clinical practice.
BRAF-Mutated mCRC: Treating With the BEACON Regimen
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Gastrointestinal oncologists consider when it is most appropriate to initiate the BEACON trial regimen of encorafenib-binimetinib-cetuximab as treatment for BRAF-mutated metastatic colorectal cancer.
Treatments for BRAF-Mutated mCRC
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Considerations for treating BRAF-mutated metastatic colorectal cancer with the combination of a BRAF inhibitor plus anti-EGFR agent based on recently presented data.
Preferences for Second-Line Therapy for mCRC
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Drs Cathy Eng and Joleen M. Hubbard explain how patients with metastatic colon cancer typically respond to initial treatment and describe the factors that impact second-line treatment decisions.
Maintenance Therapy for Metastatic CRC
ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute Recommendations regarding the selection, initiation, and length of maintenance therapy to help manage cases of metastatic colon cancer.
Applying Aggressive Therapy to Treat mCRC Up Front
ByTanios Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute The rationale for treating select patients with metastatic colorectal cancer with intensive therapy in the first-line setting vs waiting until disease progression.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib
Treatments for BRAF-Mutated mCRC
Regorafenib as Later-Line Treatment for mCRC
Novel Combinations Being Investigated for mCRC Treatment